PUMA BIOTECHNOLOGY, INC. cotiza a 10.12 USD y tiene una capitalización bursátil de $522M. En los últimos 12 meses ha facturado $231M con un margen de flujo de caja libre del 18.3%. Cotiza a 12.7 veces su flujo de caja libre (P/FCF) y a un PER de 19.6. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast c…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.20 | $-0.04 | $0.29 |
| Estimado | $0.12 | $0.07 | $-0.13 | $0.23 |
| Sorpresa | — | +185.7% | +69.2% | +26.1% |
| Métrica | PBYI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 74.5% | 57.0% | +17.5% |
| Operating Margin | 16.3% | -38.6% | +54.9% |
| Net Margin | 13.6% | -33.6% | +47.2% |
| FCF Margin | 18.3% | -13.9% | +32.1% |
| ROE | 23.9% | -40.4% | +64.3% |
| ROA | 14.4% | -32.0% | +46.4% |
| Current Ratio | 2.00 | 2.84 | -0.84 |
| Debt / Equity | 0.17 | 0.28 | -0.11 |